RxDoctor Payments Data

Igor Cherches, MD

Neurology · Houston, TXNPI 1942295522

Payments from drug & device makers

$110,981in general payments, 2019–2025

Across 1,633 payments — averaging $67.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$77K
  • Novartis$2K
  • UCB, Inc.$2K
  • Amgen$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$12,87712%
  • Speaking & faculty fees$59,05953%
  • Travel & lodging$3,4853%
  • Food & beverage$35,41432%
  • Education$1470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi147$77,357
Novartis115$2,048
UCB, Inc.73$2,035
Amgen(2 entities)74$1,968
AstraZeneca72$1,863
AbbVie(2 entities)95$1,788
Argenx US, Inc.9$1,644
Biogen87$1,603
EMD Serono, Inc.76$1,495
Amneal Pharmaceuticals LLC30$1,449
Grifols USA, LLC83$1,268
Sunovion Pharmaceuticals Inc.83$1,260
Teva Pharmaceuticals USA, Inc.62$1,052
Pfizer49$1,049
CSL Behring55$998
Eisai Inc.34$987
Abbott25$971
SK Life Science, Inc.45$943
Octapharma USA, Inc.13$834
TG Therapeutics, Inc.25$819
Neurocrine Biosciences, Inc.30$720
Genentech USA, Inc.35$700
Takeda Pharmaceuticals U.S.A., Inc.26$644
Supernus Pharmaceuticals, Inc.64$637
Lilly USA, LLC19$569
Acadia Pharmaceuticals Inc26$567
Lundbeck LLC21$389
Hospira, Inc.10$227
Biohaven Pharmaceutical Holding Company Ltd.11$227
Bristol Myers Squibb10$223
Kyowa Kirin, Inc.9$179
Biohaven Pharmaceuticals, Inc.11$177
Boston Scientific2$159
Otsuka America Pharmaceutical, Inc.7$156
Averitas Pharma Inc.2$131
Inspire Medical Systems, Inc.1$124
Mallinckrodt Hospital Products Inc.5$123
Acorda Therapeutics, Inc8$117
Assertio Therapeutics, Inc.6$108
Catalyst Pharmaceuticals, Inc.6$97
GE HealthCare4$90
E.r. Squibb & Sons, L.L.C.4$80
Impel Pharmaceuticals Inc.4$74
Avion Pharmaceuticals5$70
MDD US Operations, LLC2$67
Bausch Health US, LLC4$59
Vanda Pharmaceuticals Inc.2$54
Upsher-smith Laboratories LLC4$54
Scilex Pharmaceuticals Inc.3$51
Adamas Pharmaceuticals, Inc.2$47
Axsome Therapeutics, Inc.2$46
Corium, LLC2$45
GRT US Holding, Inc.2$44
Livanova USA, Inc.2$40
Johnson & Johnson(2 entities)2$38
Arbor Pharmaceuticals, Inc.2$35
Zyla Life Sciences, Inc.2$33
Jazz Pharmaceuticals Inc.2$31
Nevro Corp.1$30
Tanabe Pharma America, Inc.2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,981 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$15,823,274
Medicare patients
921
Services billed
274,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4641$239,030
GammakedImmune Globul G/Gly/Iga Avg 4614$212,724
VumerityDiroximel Fumarate12$100,907
Glatiramer Acetate14$39,070
Rasagiline Mesylate326$36,441
Carbidopa-Levodopa ErCarbidopa/Levodopa420$18,060
Galantamine ErGalantamine Hbr127$10,167
Gabapentin659$7,452
OngentysOpicapone11$7,253
Rivastigmine17$5,287
Pregabalin247$5,061
Pyridostigmine Bromide63$4,608
Primidone101$3,234
AmantadineAmantadine Hcl37$2,579
Dimethyl Fumarate13$2,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$1,268$239,03041 claims
BiogenVumerity$1,603$100,90712 claims
Neurocrine Biosciences, Inc.Ongentys$720$7,25311 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$1,449$6,30484 claims
Upsher-smith Laboratories LLCTopiramate$54$1,09740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →